Skip to main content
Erschienen in: Journal of Gastrointestinal Surgery 11/2007

01.11.2007

Trends in Survival after Surgery for Cholangiocarcinoma: A 30-Year Population-Based SEER Database Analysis

verfasst von: Hari Nathan, Timothy M. Pawlik, Christopher L. Wolfgang, Michael A. Choti, John L. Cameron, Richard D. Schulick

Erschienen in: Journal of Gastrointestinal Surgery | Ausgabe 11/2007

Einloggen, um Zugang zu erhalten

Abstract

The prognosis of patients with cholangiocarcinoma historically has been poor, even after surgical resection. Although data from some single-institution series indicate improvement over historical results, survival after surgical therapy for cholangiocarcinoma has not been investigated in a population-based study. We used the Surveillance, Epidemiology, and End Results database to identify patients who underwent surgery for cholangiocarcinoma from 1973 through 2002. Multivariate modeling of survival after surgery for intrahepatic cholangiocarcinoma showed an improvement in survival only within the last decade studied, resulting in a cumulative 34.4% improvement in survival from 1992 through 2002. In contrast, multivariate modeling of survival after surgery for extrahepatic cholangiocarcinoma revealed a 23.3% increase in adjusted survival per each decade studied, resulting in a cumulative 53.7% improvement from 1973 through 2002. We conclude that survival after surgery for extrahepatic cholangiocarcinoma has dramatically improved since 1973. Patients with intrahepatic cholangiocarcinoma, however, have achieved an improvement in survival largely confined to more recent years. We suggest that these trends are largely caused by developments in imaging technology, improvements in patient selection, and advances in surgical techniques.
Literatur
1.
Zurück zum Zitat Vauthey JN, Blumgart LH. Recent advances in the management of cholangiocarcinomas. Semin Liver Dis 1994;14:109–114.PubMedCrossRef Vauthey JN, Blumgart LH. Recent advances in the management of cholangiocarcinomas. Semin Liver Dis 1994;14:109–114.PubMedCrossRef
2.
Zurück zum Zitat Nakeeb A, Pitt HA, Sohn TA, Coleman J, Abrams RA, Piantadosi S, Hruban RH, Lillemoe KD, Yeo CJ, Cameron JL. Cholangiocarcinoma. A spectrum of intrahepatic, perihilar, and distal tumors. Ann Surg 1996;224:463–473; discussion 473–475.PubMedCrossRef Nakeeb A, Pitt HA, Sohn TA, Coleman J, Abrams RA, Piantadosi S, Hruban RH, Lillemoe KD, Yeo CJ, Cameron JL. Cholangiocarcinoma. A spectrum of intrahepatic, perihilar, and distal tumors. Ann Surg 1996;224:463–473; discussion 473–475.PubMedCrossRef
3.
Zurück zum Zitat Shaib Y, El-Serag HB. The epidemiology of cholangiocarcinoma. Semin Liver Dis 2004;24:115–125.PubMedCrossRef Shaib Y, El-Serag HB. The epidemiology of cholangiocarcinoma. Semin Liver Dis 2004;24:115–125.PubMedCrossRef
4.
Zurück zum Zitat Carriaga MT, Henson DE. Liver, gallbladder, extrahepatic bile ducts, and pancreas. Cancer 1995;75:171–190.PubMedCrossRef Carriaga MT, Henson DE. Liver, gallbladder, extrahepatic bile ducts, and pancreas. Cancer 1995;75:171–190.PubMedCrossRef
5.
Zurück zum Zitat Khan SA, Thomas HC, Davidson BR, Taylor-Robinson SD. Cholangiocarcinoma. Lancet 2005;366:1303–1314.PubMedCrossRef Khan SA, Thomas HC, Davidson BR, Taylor-Robinson SD. Cholangiocarcinoma. Lancet 2005;366:1303–1314.PubMedCrossRef
6.
Zurück zum Zitat Pichlmayr R, Lamesch P, Weimann A, Tusch G, Ringe B. Surgical treatment of cholangiocellular carcinoma. World J Surg 1995;19:83–88.PubMedCrossRef Pichlmayr R, Lamesch P, Weimann A, Tusch G, Ringe B. Surgical treatment of cholangiocellular carcinoma. World J Surg 1995;19:83–88.PubMedCrossRef
7.
Zurück zum Zitat Jan YY, Jeng LB, Hwang TL, Wang CS, Chen MF, Chen TJ. Factors influencing survival after hepatectomy for peripheral cholangiocarcinoma. Hepatogastroenterology 1996;43:614–619.PubMed Jan YY, Jeng LB, Hwang TL, Wang CS, Chen MF, Chen TJ. Factors influencing survival after hepatectomy for peripheral cholangiocarcinoma. Hepatogastroenterology 1996;43:614–619.PubMed
8.
Zurück zum Zitat Casavilla FA, Marsh JW, Iwatsuki S, Todo S, Lee RG, Madariaga JR, Pinna A, Dvorchik I, Fung JJ, Starzl TE. Hepatic resection and transplantation for peripheral cholangiocarcinoma. J Am Coll Surg 1997;185:429–436.PubMed Casavilla FA, Marsh JW, Iwatsuki S, Todo S, Lee RG, Madariaga JR, Pinna A, Dvorchik I, Fung JJ, Starzl TE. Hepatic resection and transplantation for peripheral cholangiocarcinoma. J Am Coll Surg 1997;185:429–436.PubMed
9.
Zurück zum Zitat Lieser MJ, Barry MK, Rowland C, Ilstrup DM, Nagorney DM. Surgical management of intrahepatic cholangiocarcinoma: A 31-year experience. J Hepatobiliary Pancreat Surg 1998;5:41–47.PubMedCrossRef Lieser MJ, Barry MK, Rowland C, Ilstrup DM, Nagorney DM. Surgical management of intrahepatic cholangiocarcinoma: A 31-year experience. J Hepatobiliary Pancreat Surg 1998;5:41–47.PubMedCrossRef
10.
Zurück zum Zitat Madariaga JR, Iwatsuki S, Todo S, Lee RG, Irish W, Starzl TE. Liver resection for hilar and peripheral cholangiocarcinomas: A study of 62 cases. Ann Surg 1998;227:70–79.PubMedCrossRef Madariaga JR, Iwatsuki S, Todo S, Lee RG, Irish W, Starzl TE. Liver resection for hilar and peripheral cholangiocarcinomas: A study of 62 cases. Ann Surg 1998;227:70–79.PubMedCrossRef
11.
Zurück zum Zitat Valverde A, Bonhomme N, Farges O, Sauvanet A, Flejou J, Belghiti J. Resection of intrahepatic cholangiocarcinoma: A western experience. J Hepatobiliary Pancreat Surg 1999;6:122–127.PubMedCrossRef Valverde A, Bonhomme N, Farges O, Sauvanet A, Flejou J, Belghiti J. Resection of intrahepatic cholangiocarcinoma: A western experience. J Hepatobiliary Pancreat Surg 1999;6:122–127.PubMedCrossRef
12.
Zurück zum Zitat Inoue K, Makuuchi M, Takayama T, Torzilli G, Yamamoto J, Shimada K, Kosuge T, Yamasaki S, Konishi M, Kinoshita T, Miyagawa S, Kawasaki S. Long-term survival and prognostic factors in the surgical treatment of mass-forming type cholangiocarcinoma. Surgery 2000;127:498–505.PubMed Inoue K, Makuuchi M, Takayama T, Torzilli G, Yamamoto J, Shimada K, Kosuge T, Yamasaki S, Konishi M, Kinoshita T, Miyagawa S, Kawasaki S. Long-term survival and prognostic factors in the surgical treatment of mass-forming type cholangiocarcinoma. Surgery 2000;127:498–505.PubMed
13.
Zurück zum Zitat Weber SM, Jarnagin WR, Klimstra D, DeMatteo RP, Fong Y, Blumgart LH. Intrahepatic cholangiocarcinoma: Resectability, recurrence pattern, and outcomes. J Am Coll Surg 2001;193:384–391.PubMedCrossRef Weber SM, Jarnagin WR, Klimstra D, DeMatteo RP, Fong Y, Blumgart LH. Intrahepatic cholangiocarcinoma: Resectability, recurrence pattern, and outcomes. J Am Coll Surg 2001;193:384–391.PubMedCrossRef
14.
Zurück zum Zitat Deoliveira ML, Cunningham SC, Cameron JL, Kamangar F, Winter JM, Lillemoe KD, Choti MA, Yeo CJ, Schulick RD. Cholangiocarcinoma: Thirty-one-year experience with 564 patients at a single institution. Ann Surg 2007;245:755–762.PubMedCrossRef Deoliveira ML, Cunningham SC, Cameron JL, Kamangar F, Winter JM, Lillemoe KD, Choti MA, Yeo CJ, Schulick RD. Cholangiocarcinoma: Thirty-one-year experience with 564 patients at a single institution. Ann Surg 2007;245:755–762.PubMedCrossRef
15.
Zurück zum Zitat Sugiura Y, Nakamura S, Iida S, Hosoda Y, Ikeuchi S, Mori S, Sugioka A, Tsuzuki T. Extensive resection of the bile ducts combined with liver resection for cancer of the main hepatic duct junction: A cooperative study of the keio bile duct cancer study group. Surgery 1994;115:445–451.PubMed Sugiura Y, Nakamura S, Iida S, Hosoda Y, Ikeuchi S, Mori S, Sugioka A, Tsuzuki T. Extensive resection of the bile ducts combined with liver resection for cancer of the main hepatic duct junction: A cooperative study of the keio bile duct cancer study group. Surgery 1994;115:445–451.PubMed
16.
Zurück zum Zitat Su CH, Tsay SH, Wu CC, Shyr YM, King KL, Lee CH, Lui WY, Liu TJ, P'eng FK. Factors influencing postoperative morbidity, mortality, and survival after resection for hilar cholangiocarcinoma. Ann Surg 1996;223:384–394.PubMedCrossRef Su CH, Tsay SH, Wu CC, Shyr YM, King KL, Lee CH, Lui WY, Liu TJ, P'eng FK. Factors influencing postoperative morbidity, mortality, and survival after resection for hilar cholangiocarcinoma. Ann Surg 1996;223:384–394.PubMedCrossRef
17.
Zurück zum Zitat Nagino M, Nimura Y, Kamiya J, Kanai M, Uesaka K, Hayakawa N, Yamamoto H, Kondo S, Nishio H. Segmental liver resections for hilar cholangiocarcinoma. Hepatogastroenterology 1998;45:7–13.PubMed Nagino M, Nimura Y, Kamiya J, Kanai M, Uesaka K, Hayakawa N, Yamamoto H, Kondo S, Nishio H. Segmental liver resections for hilar cholangiocarcinoma. Hepatogastroenterology 1998;45:7–13.PubMed
18.
Zurück zum Zitat Miyazaki M, Ito H, Nakagawa K, Ambiru S, Shimizu H, Shimizu Y, Kato A, Nakamura S, Omoto H, Nakajima N, Kimura F, Suwa T. Aggressive surgical approaches to hilar cholangiocarcinoma: Hepatic or local resection? Surgery 1998;123:131–136.PubMed Miyazaki M, Ito H, Nakagawa K, Ambiru S, Shimizu H, Shimizu Y, Kato A, Nakamura S, Omoto H, Nakajima N, Kimura F, Suwa T. Aggressive surgical approaches to hilar cholangiocarcinoma: Hepatic or local resection? Surgery 1998;123:131–136.PubMed
19.
Zurück zum Zitat Kosuge T, Yamamoto J, Shimada K, Yamasaki S, Makuuchi M. Improved surgical results for hilar cholangiocarcinoma with procedures including major hepatic resection. Ann Surg 1999;230:663–671.PubMedCrossRef Kosuge T, Yamamoto J, Shimada K, Yamasaki S, Makuuchi M. Improved surgical results for hilar cholangiocarcinoma with procedures including major hepatic resection. Ann Surg 1999;230:663–671.PubMedCrossRef
20.
Zurück zum Zitat Neuhaus P, Jonas S, Bechstein WO, Lohmann R, Radke C, Kling N, Wex C, Lobeck H, Hintze R. Extended resections for hilar cholangiocarcinoma. Ann Surg 1999;230:808–818; discussion 819.PubMedCrossRef Neuhaus P, Jonas S, Bechstein WO, Lohmann R, Radke C, Kling N, Wex C, Lobeck H, Hintze R. Extended resections for hilar cholangiocarcinoma. Ann Surg 1999;230:808–818; discussion 819.PubMedCrossRef
21.
Zurück zum Zitat Bortolasi L, Burgart LJ, Tsiotos GG, Luque-De Leon E, Sarr MG. Adenocarcinoma of the distal bile duct. A clinicopathologic outcome analysis after curative resection. Dig Surg 2000;17:36–41.PubMedCrossRef Bortolasi L, Burgart LJ, Tsiotos GG, Luque-De Leon E, Sarr MG. Adenocarcinoma of the distal bile duct. A clinicopathologic outcome analysis after curative resection. Dig Surg 2000;17:36–41.PubMedCrossRef
22.
Zurück zum Zitat Jarnagin WR, Fong Y, DeMatteo RP, Gonen M, Burke EC, Bodniewicz BSJ, Youssef BAM, Klimstra D, Blumgart LH. Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma. Ann Surg 2001;234:507–517; discussion 517–519.PubMedCrossRef Jarnagin WR, Fong Y, DeMatteo RP, Gonen M, Burke EC, Bodniewicz BSJ, Youssef BAM, Klimstra D, Blumgart LH. Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma. Ann Surg 2001;234:507–517; discussion 517–519.PubMedCrossRef
23.
Zurück zum Zitat Yoshida T, Matsumoto T, Sasaki A, Morii Y, Aramaki M, Kitano S. Prognostic factors after pancreatoduodenectomy with extended lymphadenectomy for distal bile duct cancer. Arch Surg 2002;137:69–73.PubMedCrossRef Yoshida T, Matsumoto T, Sasaki A, Morii Y, Aramaki M, Kitano S. Prognostic factors after pancreatoduodenectomy with extended lymphadenectomy for distal bile duct cancer. Arch Surg 2002;137:69–73.PubMedCrossRef
24.
Zurück zum Zitat Kondo S, Hirano S, Ambo Y, Tanaka E, Okushiba S, Morikawa T, Katoh H. Forty consecutive resections of hilar cholangiocarcinoma with no postoperative mortality and no positive ductal margins: Results of a prospective study. Ann Surg 2004;240:95–101.PubMedCrossRef Kondo S, Hirano S, Ambo Y, Tanaka E, Okushiba S, Morikawa T, Katoh H. Forty consecutive resections of hilar cholangiocarcinoma with no postoperative mortality and no positive ductal margins: Results of a prospective study. Ann Surg 2004;240:95–101.PubMedCrossRef
25.
Zurück zum Zitat Rea DJ, Munoz-Juarez M, Farnell MB, Donohue JH, Que FG, Crownhart B, Larson D, Nagorney DM. Major hepatic resection for hilar cholangiocarcinoma: Analysis of 46 patients. Arch Surg 2004;139:514–523; discussion 523–525.PubMedCrossRef Rea DJ, Munoz-Juarez M, Farnell MB, Donohue JH, Que FG, Crownhart B, Larson D, Nagorney DM. Major hepatic resection for hilar cholangiocarcinoma: Analysis of 46 patients. Arch Surg 2004;139:514–523; discussion 523–525.PubMedCrossRef
26.
Zurück zum Zitat Nishio H, Nagino M, Nimura Y. Surgical management of hilar cholangiocarcinoma: The Nagoya experience. HPB 2005;7:259–262.PubMed Nishio H, Nagino M, Nimura Y. Surgical management of hilar cholangiocarcinoma: The Nagoya experience. HPB 2005;7:259–262.PubMed
27.
Zurück zum Zitat Liu CL, Fan ST, Lo CM, Tso WK, Lam CM, Wong J. Improved operative and survival outcomes of surgical treatment for hilar cholangiocarcinoma. Br J Surg 2006;93:1488–1494.PubMedCrossRef Liu CL, Fan ST, Lo CM, Tso WK, Lam CM, Wong J. Improved operative and survival outcomes of surgical treatment for hilar cholangiocarcinoma. Br J Surg 2006;93:1488–1494.PubMedCrossRef
28.
Zurück zum Zitat National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch. Surveillance, epidemiology, and end results (SEER) program (http://www.seer.cancer.gov) SEER*Stat database: Incidence, SEER 17 regs public-use, Nov 2005 sub (1973–2003 varying), linked to county attributes, total U.S., 1969–2003 counties. Released April 2006, based on the November 2005 submission. National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch. Surveillance, epidemiology, and end results (SEER) program (http://​www.​seer.​cancer.​gov) SEER*Stat database: Incidence, SEER 17 regs public-use, Nov 2005 sub (1973–2003 varying), linked to county attributes, total U.S., 1969–2003 counties. Released April 2006, based on the November 2005 submission.
29.
Zurück zum Zitat Fritz AG. International Classification of Diseases for Oncology: ICD-O, 3rd ed. Geneva: World Health Organization, 2000. Fritz AG. International Classification of Diseases for Oncology: ICD-O, 3rd ed. Geneva: World Health Organization, 2000.
30.
Zurück zum Zitat Welzel TM, McGlynn KA, Hsing AW, O’Brien TR, Pfeiffer RM. Impact of classification of hilar cholangiocarcinomas (klatskin tumors) on the incidence of intra- and extrahepatic cholangiocarcinoma in the united states. J Natl Cancer Inst 2006;98:873–875.PubMedCrossRef Welzel TM, McGlynn KA, Hsing AW, O’Brien TR, Pfeiffer RM. Impact of classification of hilar cholangiocarcinomas (klatskin tumors) on the incidence of intra- and extrahepatic cholangiocarcinoma in the united states. J Natl Cancer Inst 2006;98:873–875.PubMedCrossRef
31.
Zurück zum Zitat Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457–481.CrossRef Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457–481.CrossRef
32.
Zurück zum Zitat Brown CC. The statistical comparison of relative survival rates. Biometrics 1983;39:941–948.PubMedCrossRef Brown CC. The statistical comparison of relative survival rates. Biometrics 1983;39:941–948.PubMedCrossRef
34.
Zurück zum Zitat Cox DR. Regression models and life-tables. J R Stat Soc B 1972;34:187–220. Cox DR. Regression models and life-tables. J R Stat Soc B 1972;34:187–220.
35.
Zurück zum Zitat Rubin DB. Multiple imputation for nonresponse in surveys. New York: Wiley, 1987. Rubin DB. Multiple imputation for nonresponse in surveys. New York: Wiley, 1987.
36.
Zurück zum Zitat Rubin DB, Schenker N. Multiple imputation in health-care databases: An overview and some applications. Stat Med 1991;10:585–598.PubMedCrossRef Rubin DB, Schenker N. Multiple imputation in health-care databases: An overview and some applications. Stat Med 1991;10:585–598.PubMedCrossRef
38.
Zurück zum Zitat Royston P. Multiple imputation of missing values: Update of ICE. Stat J 2005;5:527–536. Royston P. Multiple imputation of missing values: Update of ICE. Stat J 2005;5:527–536.
39.
Zurück zum Zitat Kooby DA, Jarnagin WR. Surgical management of hepatic malignancy. Cancer Invest 2004;22:283–303.PubMedCrossRef Kooby DA, Jarnagin WR. Surgical management of hepatic malignancy. Cancer Invest 2004;22:283–303.PubMedCrossRef
40.
Zurück zum Zitat Cameron JL, Riall TS, Coleman J, Belcher KA. One thousand consecutive pancreaticoduodenectomies. Ann Surg 2006;244:10–15.PubMedCrossRef Cameron JL, Riall TS, Coleman J, Belcher KA. One thousand consecutive pancreaticoduodenectomies. Ann Surg 2006;244:10–15.PubMedCrossRef
41.
Zurück zum Zitat Pitt HA, Nakeeb A, Abrams RA, Coleman J, Piantadosi S, Yeo CJ, Lillemore KD, Cameron JL. Perihilar cholangiocarcinoma. postoperative radiotherapy does not improve survival. Ann Surg 1995;221:788–797; discussion 797–798.PubMedCrossRef Pitt HA, Nakeeb A, Abrams RA, Coleman J, Piantadosi S, Yeo CJ, Lillemore KD, Cameron JL. Perihilar cholangiocarcinoma. postoperative radiotherapy does not improve survival. Ann Surg 1995;221:788–797; discussion 797–798.PubMedCrossRef
42.
Zurück zum Zitat Hejna M, Pruckmayer M, Raderer M. The role of chemotherapy and radiation in the management of biliary cancer: A review of the literature. Eur J Cancer 1998;34:977–986.PubMedCrossRef Hejna M, Pruckmayer M, Raderer M. The role of chemotherapy and radiation in the management of biliary cancer: A review of the literature. Eur J Cancer 1998;34:977–986.PubMedCrossRef
43.
Zurück zum Zitat Khan SA, Davidson BR, Goldin R, Pereira SP, Rosenberg WM, Taylor-Robinson SD, Thillainayagam AV, Thomas HC, Thursz MR, Wasan H, British Society of Gastroenterology. Guidelines for the diagnosis and treatment of cholangiocarcinoma: Consensus document. Gut 2002;51(6):7–9.CrossRef Khan SA, Davidson BR, Goldin R, Pereira SP, Rosenberg WM, Taylor-Robinson SD, Thillainayagam AV, Thomas HC, Thursz MR, Wasan H, British Society of Gastroenterology. Guidelines for the diagnosis and treatment of cholangiocarcinoma: Consensus document. Gut 2002;51(6):7–9.CrossRef
44.
Zurück zum Zitat Alden ME, Mohiuddin M. The impact of radiation dose in combined external beam and intraluminal ir-192 brachytherapy for bile duct cancer. Int J Radiat Oncol Biol Phys 1994;28:945–951.PubMed Alden ME, Mohiuddin M. The impact of radiation dose in combined external beam and intraluminal ir-192 brachytherapy for bile duct cancer. Int J Radiat Oncol Biol Phys 1994;28:945–951.PubMed
45.
Zurück zum Zitat Czito BG, Anscher MS, Willett CG. Radiation therapy in the treatment of cholangiocarcinoma. Oncology (Williston Park) 2006;20:873–884; discussion 886–888, 893–895. Czito BG, Anscher MS, Willett CG. Radiation therapy in the treatment of cholangiocarcinoma. Oncology (Williston Park) 2006;20:873–884; discussion 886–888, 893–895.
Metadaten
Titel
Trends in Survival after Surgery for Cholangiocarcinoma: A 30-Year Population-Based SEER Database Analysis
verfasst von
Hari Nathan
Timothy M. Pawlik
Christopher L. Wolfgang
Michael A. Choti
John L. Cameron
Richard D. Schulick
Publikationsdatum
01.11.2007
Verlag
Springer-Verlag
Erschienen in
Journal of Gastrointestinal Surgery / Ausgabe 11/2007
Print ISSN: 1091-255X
Elektronische ISSN: 1873-4626
DOI
https://doi.org/10.1007/s11605-007-0282-0

Weitere Artikel der Ausgabe 11/2007

Journal of Gastrointestinal Surgery 11/2007 Zur Ausgabe

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren. 

Wie sieht der OP der Zukunft aus?

04.05.2024 DCK 2024 Kongressbericht

Der OP in der Zukunft wird mit weniger Personal auskommen – nicht, weil die Technik das medizinische Fachpersonal verdrängt, sondern weil der Personalmangel es nötig macht.

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Recycling im OP – möglich, aber teuer

02.05.2024 DCK 2024 Kongressbericht

Auch wenn sich Krankenhäuser nachhaltig und grün geben – sie tragen aktuell erheblich zu den CO2-Emissionen bei und produzieren jede Menge Müll. Ein Pilotprojekt aus Bonn zeigt, dass viele Op.-Abfälle wiederverwertet werden können.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.